However, given that GDYO was selectively active against DNMT3A-mutant AML cells, and not universally active against all cell lines tested, we hypothesized that there are other, cell line-specific factors that impact GDYO bioactivity. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.